SymBiosis Capital Partners, LLC
SymBiosis Capital Partners, LLC is a Series C+, late-pre-clinical and clinical-stage fund in the US writing $5M–$15M checks into Healthcare, biotherapeutics, manufacturing, biologics, cell-therapy, genetic-medicine, small-molecules, life-sciences and biotechnology.
- Stages
- Series C+, late-pre-clinical, clinical-stage
- Sectors
- Healthcare, biotherapeutics, manufacturing, biologics, cell-therapy, genetic-medicine, small-molecules, life-sciences, biotechnology
- Check size
- $5M–$15M
- Invests in
- US-wide
- Actively investing
- Yes
- Founded
- 2021
- Assets under management
- $357M
- Website
- symbiosis.vc
Thesis
SymBiosis Capital Partners is a venture capital firm specializing in domestic life sciences and biotechnology investments in both private venture capital and public markets. The firm focuses on biotherapeutics and manufacturing sectors, investing across biologics, cell therapy, genetic medicine, and small molecules. They invest across disease areas, focusing on life-threatening diseases with objective, well-established endpoints. The firm primarily invests in companies based in the United States and serves as both a lead and syndicate participant in financing rounds. Initial investments typically range from $5 million to $15 million, with the potential to scale to $30 million or more across multiple financing rounds. As of December 31, 2025, SymBiosis manages approximately $357,151,088 in assets under management across two funds: SymBiosis, LLC and SymBiosis II, LLC.
Common questions
Does SymBiosis Capital Partners, LLC invest at the Series C+ stage?
Yes. SymBiosis Capital Partners, LLC lists Series C+, late-pre-clinical and clinical-stage among the stages it invests in.
What check size does SymBiosis Capital Partners, LLC write?
SymBiosis Capital Partners, LLC writes $5M–$15M checks.
Where does SymBiosis Capital Partners, LLC invest?
SymBiosis Capital Partners, LLC invests in the US.